ATE296638T1 - Behandlung von nierenzellen-karzinom - Google Patents

Behandlung von nierenzellen-karzinom

Info

Publication number
ATE296638T1
ATE296638T1 AT00107100T AT00107100T ATE296638T1 AT E296638 T1 ATE296638 T1 AT E296638T1 AT 00107100 T AT00107100 T AT 00107100T AT 00107100 T AT00107100 T AT 00107100T AT E296638 T1 ATE296638 T1 AT E296638T1
Authority
AT
Austria
Prior art keywords
treatment
cell carcinoma
renal cell
renal
carcinoma
Prior art date
Application number
AT00107100T
Other languages
German (de)
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE296638T1 publication Critical patent/ATE296638T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT00107100T 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom ATE296638T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
ATE296638T1 true ATE296638T1 (de) 2005-06-15

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00107100T ATE296638T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom
AT05002952T ATE419002T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05002952T ATE419002T1 (de) 1999-04-08 2000-04-06 Behandlung von nierenzellen-karzinom

Country Status (23)

Country Link
EP (2) EP1043025B1 (https=)
JP (2) JP3712914B2 (https=)
CN (1) CN1367702A (https=)
AR (1) AR029160A1 (https=)
AT (2) ATE296638T1 (https=)
AU (2) AU777406B2 (https=)
BR (1) BR0009644A (https=)
CA (1) CA2303752A1 (https=)
CO (1) CO5170412A1 (https=)
CY (1) CY1108919T1 (https=)
DE (2) DE60041291D1 (https=)
DK (2) DK1043025T3 (https=)
ES (2) ES2239953T3 (https=)
HU (1) HU230271B1 (https=)
MX (1) MXPA00003401A (https=)
MY (1) MY155221A (https=)
NO (1) NO328983B1 (https=)
NZ (1) NZ514629A (https=)
PE (1) PE20010026A1 (https=)
PT (2) PT1043025E (https=)
TW (2) TWI310314B (https=)
WO (1) WO2000061174A2 (https=)
ZA (1) ZA200108169B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
ES2891564T3 (es) 2010-04-01 2022-01-28 Oncorena Ab Tratamiento mejorado del carcinoma de células renales
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
WO2024186735A1 (en) * 2023-03-03 2024-09-12 Memorial Sloan-Kettering Cancer Center Methods and compositions for the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
CA2303752A1 (en) * 1999-04-08 2000-10-08 Schering Corporation Renal cell carcinoma treatment

Also Published As

Publication number Publication date
HK1032533A1 (en) 2001-07-27
JP2001288110A (ja) 2001-10-16
DK1535623T3 (da) 2009-04-27
ZA200108169B (en) 2003-01-06
MY155221A (en) 2015-09-30
CA2303752A1 (en) 2000-10-08
JP2000319196A (ja) 2000-11-21
EP1535623A1 (en) 2005-06-01
NO20014851L (no) 2001-12-07
TWI310314B (en) 2009-06-01
DE60020442D1 (de) 2005-07-07
NZ514629A (en) 2004-02-27
CN1367702A (zh) 2002-09-04
HUP0200781A2 (en) 2002-08-28
DE60020442T2 (de) 2006-05-04
AU2004242454A1 (en) 2005-01-20
CO5170412A1 (es) 2002-06-27
DE60041291D1 (de) 2009-02-12
EP1043025A3 (en) 2000-12-20
TW200526243A (en) 2005-08-16
NO328983B1 (no) 2010-07-05
JP3712914B2 (ja) 2005-11-02
CY1108919T1 (el) 2014-07-02
EP1043025A2 (en) 2000-10-11
WO2000061174A2 (en) 2000-10-19
NO20014851D0 (no) 2001-10-05
HU230271B1 (hu) 2015-11-30
AU2004242454B2 (en) 2007-02-15
AR029160A1 (es) 2003-06-18
BR0009644A (pt) 2002-01-08
JP4721488B2 (ja) 2011-07-13
HK1075417A1 (en) 2005-12-16
AU777406B2 (en) 2004-10-14
DK1043025T3 (da) 2005-07-04
PT1535623E (pt) 2009-03-19
ES2239953T3 (es) 2005-10-16
PE20010026A1 (es) 2001-02-05
HUP0200781A3 (en) 2002-09-30
MXPA00003401A (es) 2002-03-08
ATE419002T1 (de) 2009-01-15
AU4204400A (en) 2000-11-14
PT1043025E (pt) 2005-09-30
WO2000061174A3 (en) 2001-01-25
EP1043025B1 (en) 2005-06-01
ES2319777T3 (es) 2009-05-12
EP1535623B1 (en) 2008-12-31

Similar Documents

Publication Publication Date Title
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE60001421D1 (de) Behandlung von abgas
ATE260332T1 (de) Behandlung von textilien
ATE300597T1 (de) Behandlung von geweben
ATE301617T1 (de) Behandlung von wasser
EP1240280A4 (en) PROCESS FOR TREATING COAL
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
DE69939575D1 (de) Entdeckung von Diensten in unmittelbarer Nähe
DE69836735D1 (de) Behandlung von darmverstopfung
DE69817446D1 (de) Behandlung von diabetes
FI20000863A0 (fi) Uusi hoitomenetelmä
DE60118179D1 (de) Behandlung von zirkulierenden wassersystemen
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
EP1117431A4 (en) TREATMENT OF ACIDOSIS
ATE269391T1 (de) Wäschebehandlung
DE60021065D1 (de) Virus behandlung
EP1239851A4 (en) TREATMENT OF HYPERPROLIFERATIVE DISORDERS
DE69932235D1 (de) Behandlung von herzhypertrophie
DE60041291D1 (de) Behandlung von Nierenzellen-Karzinom
NO20013337L (no) Ny behandling
DE60103685D1 (de) Behandlung von Poriomania
DE60026821D1 (de) Behandlung von bohrspülung
ATE302165T1 (de) Wasserbehandlung
DE60011060D1 (de) Virus behandlung
ATE290060T1 (de) Wäschebehandlung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1043025

Country of ref document: EP